Advertisement

European Journal of Clinical Pharmacology

, Volume 68, Issue 1, pp 65–71 | Cite as

New users of antidepressant medications: first episode duration and predictors of discontinuation

  • Christine Y. LuEmail author
  • Elizabeth Roughead
Pharmacoepidemiology and Prescription

Abstract

Purpose

Clinical guidelines recommend that antidepressant treatment should be continued for at least 6 months. We examined persistence in patients initiated on an antidepressant medication and factors associated with treatment cessation.

Methods

We conducted a cohort study of antidepressant initiators in the Australian veteran population. Patients included were those who had filled at least one prescription for an antidepressant between 2005 and 2008 but had no antidepressants in the preceding 12 months. Kaplan-Meier was used to assess the treatment duration and Cox regression estimated the hazard ratio (HR) of ceasing antidepressant therapy.

Results

There were 91,183 antidepressant users of which more than 50% were prevalent users. Among new users (n = 28,585), 50% discontinued within 6 months, and 61% within 12 months. The median duration for antidepressant treatment was 175 days [95% confidence interval (CI), 168–180]. Patients who received psychological or psychiatrist care around the time of initiation had higher persistence (HR: 0.86, CI: 0.77–0.95 and HR: 0.67, CI: 0.61–0.75 respectively), those with psychiatric disorders and dementia were also more persistent (HR: 0.82, CI: 0.77–0.88 and HR: 0.77, CI: 0.72–0.83 respectively). In contrast, patients with cancer and multi-morbidities had a higher risk of discontinuation (HR: 1.10, CI: 1.03–1.18 and HR: 1.16, CI: 1.05–1.28 respectively).

Conclusions

This analysis indicates persistence with antidepressants in the Australian veteran patients is inconsistent with clinical guidelines, with the majority of initiating patients provided with insufficient duration. Enhanced management of patients with characteristics associated with shorter persistence, including cancer and multi-morbidities, may improve antidepressant use.

Keywords

Persistence Determinants Antidepressant Mental health 

Notes

Acknowledgements

The authors thank the Australian Department of Veterans’ Affairs for providing the data used in this study.

Funding/support

Dr C. Lu was supported by an Australian National Health and Medical Research Council Public Health Training Fellowship. Dr E Roughead was supported by an Australian Research Council Future Fellowship. The funders had no role in study design, data collection and analysis, or preparation of the manuscript.

Location of work

This work was conducted at the Quality Use of Medicines and Pharmacy Research Centre, Sansom Institute, University of South Australia.

Conflict of interest

None.

Description of authors’ roles

Christine Lu (C.L.) and Elizabeth Roughead (E.R.) designed the study; C.L. conducted the analyses; C.L. and E.R. contributed to the interpretation of the data; C.L. drafted and reviewed the manuscript; E.R. reviewed the manuscript. All authors read and approved the final manuscript.

References

  1. 1.
    Moussavi S, Chatterji S, Verdes E, Tandon A, Patel V, Ustun B (2007) Depression, chronic diseases, and decrements in health: results from the World Health Surveys. Lancet 370(9590):851–858PubMedCrossRefGoogle Scholar
  2. 2.
    Australian Bureau of Statistics (2008) National Survey of Mental Health and Wellbeing: summary of results. http://www.abs.gov.au. Accessed 18 October 2010
  3. 3.
    Clarke DM, Currie KC (2009) Depression, anxiety and their relationship with chronic diseases: a review of the epidemiology, risk and treatment evidence. Med J Aust 190(7 Suppl):S54–S60PubMedGoogle Scholar
  4. 4.
    Prince M, Patel V, Saxena S, Maj M, Maselko J, Phillips MR, Rahman A (2007) No health without mental health. Lancet 370(9590):859–877PubMedCrossRefGoogle Scholar
  5. 5.
    UK National Institute for Health and Clinical Excellence (2009) Depression in adults with a chronic physical health problem: treatment and management (clinical guideline 91). NIHCE, LondonGoogle Scholar
  6. 6.
    UK National Institute for Health and Clinical Excellence (2009) Depression: the treatment and management of depression in adults (clinical guideline 90). NIHCE, LondonGoogle Scholar
  7. 7.
    Ellis PM, Smith DA (2002) Treating depression: the beyondblue guidelines for treating depression in primary care. "Not so much what you do but that you keep doing it". Med J Aust 176(Suppl):S77–S83PubMedGoogle Scholar
  8. 8.
    Geddes JR, Carney SM, Davies C, Furukawa TA, Kupfer DJ, Frank E, Goodwin GM (2003) Relapse prevention with antidepressant drug treatment in depressive disorders: a systematic review. Lancet 361(9358):653–661PubMedCrossRefGoogle Scholar
  9. 9.
    Lu CY, Barratt J, Vitry A, Roughead E (2011) Charlson and Rx-Risk comorbidity indices were predictive of mortality in the Australian health care setting. J Clin Epidemiol 64(2):223–228PubMedCrossRefGoogle Scholar
  10. 10.
    Roughead E, Ramsay E, Priess K, Barratt J, Ryan P, Gilbert AL (2009) Medication adherence, first episode duration, overall duration and time without therapy: the example of bisphosphonates. Pharmacoepidemiol Drug Saf 18(1):69–75. doi: 10.1002/pds.1687 PubMedCrossRefGoogle Scholar
  11. 11.
    World Health Organization Collaborating Centre for Drug Statistics Methodology (2010) International language for drug utilization research. Available from: www.whocc.no/. Accessed Feb 01, 2010
  12. 12.
    Australian Government Department of Health and Ageing (2009) Schedule of pharmaceutical benefits. http://www.pbs.gov.au/. Accessed Feb 01, 2010
  13. 13.
    Australian Government Department of Health and Ageing (2009) Medicare benefits schedule. http://www.health.gov.au/internet/mbsonline/publishing.nsf/Content/Medicare-Benefits-Schedule-MBS-1. Accessed Feb 01, 2010
  14. 14.
    Australian Government Department of Veterans' Affairs (2008) Australian veterans and war widows. Your lives, your needs, 5th ed. DVA, CanberraGoogle Scholar
  15. 15.
    Australian Government Department of Veterans' Affairs (2010) Treatment population statistics. Quarterly report—June 2010. http://www.dva.gov.au/aboutDVA/Statistics/Pages/Statistics.aspx#treat. Accessed May 03, 2011
  16. 16.
    McManus P, Mant A, Mitchell P, Britt H, Dudley J (2003) Use of antidepressants by general practitioners and psychiatrists in Australia. Aust N Z J Psychiatry 37(2):184–189PubMedCrossRefGoogle Scholar
  17. 17.
    Donnelly N, McManus P, Dudley J, Hall W (2000) Impact of increasing the re-supply interval on the seasonality of subsidised prescription use in Australia. Aust N Z J Public Health 24(6):603–606PubMedCrossRefGoogle Scholar
  18. 18.
    Australian Bureau of Statistics (2008) SEIFA: socio-economic indexes for areas 2006. http://www.abs.gov.au. Accessed Aug 18, 2010
  19. 19.
    Quan H, Sundararajan V, Halfon P, Fong A, Burnand B, Luthi JC, Saunders LD, Beck CA, Feasby TE, Ghali WA (2005) Coding algorithms for defining comorbidities in ICD-9-CM and ICD-10 administrative data. Med Care 43(11):1130–1139PubMedCrossRefGoogle Scholar
  20. 20.
    Sloan KL, Sales AE, Liu CF, Fishman P, Nichol P, Suzuki NT, Sharp ND (2003) Construction and characteristics of the RxRisk-V: a VA-adapted pharmacy-based case-mix instrument. Med Care 41(6):761–774. doi: 10.1097/01.MLR.0000064641.84967.B7 PubMedGoogle Scholar
  21. 21.
    Johnson ML, El-Serag HB, Tran TT, Hartman C, Richardson P, Abraham NS (2006) Adapting the Rx-Risk-V for mortality prediction in outpatient populations. Med Care 44(8):793–797PubMedCrossRefGoogle Scholar
  22. 22.
    McManus P, Mant A, Mitchell P, Dudley J (2004) Length of therapy with selective serotonin reuptake inhibitors and tricyclic antidepressants in Australia. Aust N Z J Psychiatry 38(6):450–454PubMedCrossRefGoogle Scholar
  23. 23.
    Demyttenaere K, Enzlin P, Dewe W, Boulanger B, De Bie J, De Troyer W, Mesters P (2001) Compliance with antidepressants in a primary care setting, 1: beyond lack of efficacy and adverse events. J Clin Psychiatry 62(Suppl 22):30–33PubMedGoogle Scholar
  24. 24.
    Hunot VM, Horne R, Leese MN, Churchill RC (2007) A cohort study of adherence to antidepressants in primary care: the influence of antidepressant concerns and treatment preferences. Prim Care Companion J Clin Psychiatry 9(2):91–99PubMedCrossRefGoogle Scholar
  25. 25.
    Hansen DG, Vach W, Rosholm JU, Sondergaard J, Gram LF, Kragstrup J (2004) Early discontinuation of antidepressants in general practice: association with patient and prescriber characteristics. Fam Pract 21(6):623–629PubMedCrossRefGoogle Scholar
  26. 26.
    McManus P, Mant A, Mitchell PB, Montgomery WS, Marley J, Auland ME (2000) Recent trends in the use of antidepressant drugs in Australia, 1990–1998. Med J Aust 173(9):458–461PubMedGoogle Scholar
  27. 27.
    UK National Institute for Health and Clinical Excellence (2007) Management of anxiety (panic disorder, with or without agoraphobia and generalised anxiety disorder) in adults in primary, secondary and community care (clinical guideline 22 amended). NIHCE, LondonGoogle Scholar
  28. 28.
    Hollingworth SA, Burgess PM, Whiteford HA (2010) Affective and anxiety disorders: prevalence, treatment and antidepressant medication use. Aust N Z J Psychiatry 44(6):513–519. doi: 10.3109/00048670903555138 PubMedGoogle Scholar
  29. 29.
    Gichangi A, Andersen M, Kragstrup J, Vach W (2006) Analysing duration of episodes of pharmacological care: an example of antidepressant use in Danish general practice. Pharmacoepidemiol Drug Saf 15(3):167–177. doi: 10.1002/pds.1160 PubMedCrossRefGoogle Scholar

Copyright information

© Springer-Verlag 2011

Authors and Affiliations

  1. 1.Department of Population MedicineHarvard Medical School and the Harvard Pilgrim Health Care InstituteBostonUSA
  2. 2.Quality Use of Medicines and Pharmacy Research Centre, Sansom InstituteUniversity of South AustraliaAdelaideAustralia

Personalised recommendations